Skip to main content
Figure 2 | BMC Research Notes

Figure 2

From: Vorinostat synergizes with ridaforolimus and abrogates the ridaforolimus-induced activation of AKT in synovial sarcoma cells

Figure 2

Effects of ridaforolimus and vorinostat on AKT in HS-SY-II and SYO-I. Representative Western blot analysis of cell lysates of HS-SY-II and SYO-I treated with ridaforolimus (15 nM), vorinostat (500 nM), or their combination for 72 hours. Cell lysates were subjected to immunoblot analysis with phospho-AKT-ser473, total AKT, and β-actin antibodies. This experiment was undertaken twice. Semi-quantification of p-AKT-ser473 is depicted under each band. Levels of p-AKT-ser473 bands were normalized to their corresponding total-AKT bands, which were normalized to their corresponding β-actin bands.

Back to article page